Introduction
============

Lung cancer is the leading cause of cancer mortalities worldwide ([@b1-ol-07-06-1819]). Among all cases, \~80% are classified as non-small cell lung cancer (NSCLC) and the remaining 20% are identified as SCLC. In addition to genetic lesions, including gene mutation, genomic insertion/deletion and translocation, erroneous epigenetic modifications are often involved in the development and progression of cancer ([@b2-ol-07-06-1819]). Silencing of tumor suppressor genes owing to aberrant promoter DNA methylation ([@b3-ol-07-06-1819]) and faulty activation of oncogenes caused by genomic DNA hypomethylation ([@b4-ol-07-06-1819]) are common in cancer cells. Additionally, overexpression of histone deacetylases (HDACs), which induce transcriptional silencing by catalyzing the removal of acetyl moieties from histones, represents another modality of epigenetic defect that contributes to cancer development ([@b5-ol-07-06-1819],[@b6-ol-07-06-1819]). The use of small-molecule chemical agents to reactivate the expression of tumor suppressor genes or to repress oncogenes epigenetically has emerged as a promising approach to eradicate cancer. Accordingly, inhibitors of DNA methyltransferases (DNMTi) and HDACs (HDACi) represent the two major classes of epigenetic antitumor agents.

In addition to protein coding genes, the expression of non-coding RNA transcripts, including microRNAs (miRNAs), is often dysregulated at the epigenetic level in cancer cells ([@b7-ol-07-06-1819],[@b8-ol-07-06-1819]). miRNAs are small RNAs (\~22 nucleotides) that regulate gene expression by binding to the 3′-untranslated regions of target gene transcripts to induce translational repression or transcript degradation. Depending on the biological function of the target gene products, miRNAs are involved in diverse biological processes, including cell proliferation and differentiation. With regard to cancer development, miRNAs were shown to exhibit oncogenic ([@b9-ol-07-06-1819]--[@b11-ol-07-06-1819]) and tumor suppressive ([@b12-ol-07-06-1819]--[@b14-ol-07-06-1819]) properties, respectively. Treatment of cancer cells with HDACi and DNMTi separately or in combination was shown to modulate miRNA expression ([@b15-ol-07-06-1819]--[@b21-ol-07-06-1819]), indicating the possibility of suppressing cancer cell growth and spread by targeting miRNA expression.

In addition to DNA methylation and histone acetylation, histone lysine methylation is involved in the epigenetic regulation of gene expression and represents another target of dysregulation. Depending on the position of the lysine residues to be methylated, histone methylation is involved in transcriptional activation and repression. Notably, the mono- and di-methylation of histone H3 at lysine 9 (H3K9me1 and H3K9me2) are associated with transcriptional repression in euchromatin ([@b22-ol-07-06-1819]). The enzyme responsible for H3K9me1 and H3K9me2 formation is G9a histone methyltransferase ([@b23-ol-07-06-1819]). G9a expression is upregulated in various types of human cancer ([@b24-ol-07-06-1819],[@b25-ol-07-06-1819]), which indicates that the enzymatic activity is oncogenic. Consistent with this, the promoter regions of the aberrantly silenced tumor suppressor genes are marked by an increased level of H3K9me2 in cancer cells ([@b26-ol-07-06-1819]), and H3K9me1 and H3K9me2 are erased from the promoters of reactivated tumor suppressor genes ([@b27-ol-07-06-1819]). Additionally, the silencing of G9a expression by RNA interference reduces the invasiveness and metastatic potential of human lung cancer cells ([@b28-ol-07-06-1819]) and inhibits the growth of prostate cancer cells ([@b29-ol-07-06-1819]). These observations indicate a functional association between G9a activity and cancer development. Treatment of cells with BIX01294, a chemical inhibitor specific to G9a, results in a decline of the cellular H3K9me2 content ([@b30-ol-07-06-1819]). The reduction of proliferation, motility and invasiveness of human neuroblastoma cells following BIX01294 treatment ([@b31-ol-07-06-1819]) further indicates the use of this chemical as an antitumor agent. To examine whether specific miRNAs are involved in the tumor suppressive effect of G9a inhibition, a microarray analysis was performed in the current study to probe the global change in miRNA expression levels in human NSCLC H1299 cells following BIX01294 treatment.

Materials and methods
=====================

Cell culture
------------

The human NSCLC cells, H1299 (CRL-5803) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in RPMI-1640 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 10% non heat-inactivated fetal bovine serum (ATCC) and 1% antibiotic-antimycotic solution (Corning Inc., Acton, MA, USA). Four hours prior to drug treatment, 5×10^4^ proliferating H1299 cells were seeded into each well of a 12-well culture plate. BIX01294 (Stemgent, Cambridge, MA, USA) was reconstituted in dimethyl sulfoxide (DMSO), and diluted 10 times in 1× phosphate-buffered saline (PBS) immediately prior to use. The working BIX01294 solution was added directly to the culture medium to a final concentration of 4 μM. For the cells that were receiving the mock treatment, an equal volume of PBS-diluted DMSO was added. The cells were incubated at 37°C in a 5% CO~2~ atmosphere for 48 h prior to sample collection.

Total RNA extraction
--------------------

H1299 cells were lysed in TRIzol reagent (Life Technologies). The total RNA fraction was harvested following a chloroform extraction and further purified using the Direct-Zol purification kit (Zymo Research Corporation, Irvine, CA, USA). RNA quantity and quality were analyzed using a a NanoVue spectrophotometer (GE Healthcare, Pittsburg, PA, USA) and Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA), respectively.

miRNA microarray analysis
-------------------------

A genome-wide miRNA expression profiling experiment was performed by LC Sciences (Houston, TX, USA). The probes for a total of 2,019 unique mature human miRNAs (Sanger miRBase Release 19.0; Wellcome Trust Sanger Institute, Hinxton, UK) were printed on the microarray in quadruplicate. Equal quantities of total RNA from three independent preparations of each sample group (mock versus BIX01294 treatment) were pooled for the miRNA microarray experiment. Fluorescent signals were background subtracted and normalized using the locally weighted scatterplot smoothing method. A two-tailed t-test (P\<0.01 was identified to indicate a statistically significant difference) was performed to identify the differentially expressed miRNAs.

Quantitative real-time polymerase chain reaction (qPCR) analysis of miRNAs
--------------------------------------------------------------------------

qPCR analysis of the expression level of individual miRNAs was performed according to instructions from Life Technologies (User bulletin no. 4465407, Jan 2013 version C) with minor modifications. Briefly, reverse transcription (RT) was conducted using the Taqman microRNA Reverse Transcription kit. In each reaction, 50 ng total RNA was reverse transcribed in the presence of 6 μl 100-fold diluted RT primer stock solution, 2 mM deoxyribonucleotide triphosphate, 3.8 units of RNase inhibitor and 150 units of MultiScribe reverse transcriptase. The RT product was diluted five times in nuclease-free water. In each subsequent PCR reaction, 8 μl of the diluted RT product was used with 1× Taqman microRNA assay and 1× Taqman Universal Master Mix (Life Technologies). Triplicate measurements for each miRNA were performed, and the analysis was performed with the three independent preparations of total RNA samples harvested from each sample group. The expression level of individual miRNAs was normalized to that of small nucleolar RNA, RNU24, and the change in expression level was calculated using the 2^−ΔΔCt^ method. A two-tailed t-test (P\<0.05 was identified to indicate a statistically significant difference) was performed to identify the differentially expressed miRNAs. All Taqman miRNA assays for mature human miRNAs and RNU24 were purchased from Life Technologies.

miRNA target prediction
-----------------------

Potential target genes of miRNAs were predicted using the miRNA Target Prediction and Functional Study Database ([www.mirdb.org](www.mirdb.org)) ([@b32-ol-07-06-1819],[@b33-ol-07-06-1819]). Enrichment analysis for disease-associated genes was performed using the WEB-based Gene Set Analysis Toolkit (<http://bioinfo.vanderbilt.edu/webgestalt/>) ([@b34-ol-07-06-1819]). The functional annotation of the genes was further inquired from the Gene References Into Functions (GeneRIFs) on the National Center for Biotechnology Information website (<http://www.ncbi.nlm.nih.gov/gene/>).

Statistical analysis
--------------------

All statistical analyses were performed using a two-tailed Student's t-test. P\<0.01 and P\<0.05 were considered to indicate a statistically significant difference in miRNA microarray and qPCR analysis, respectively.

Results
=======

G9a regulates the expression of miRNAs in human lung cancer cells
-----------------------------------------------------------------

To examine whether G9a regulates the expression of miRNAs in human lung cancer cells, a microarray analysis was performed to study the change in the global miRNA expression pattern in H1299 cells in the presence and absence of BIX01294. Among the 2,019 mature human miRNAs scrutinized, only 51 of them were found to be differentially expressed ([Table I](#tI-ol-07-06-1819){ref-type="table"}). To identify the miRNAs that showed a robust change in expression level, the focus was on the miRNAs that exhibited a signal intensity of 500 units in at least one of the sample groups ([@b35-ol-07-06-1819]). Of the 51 differentially expressed miRNAs, 10 passed this selection criterion. Among the 10 miRNAs, six showed downregulation and the remaining four showed upregulation, following BIX01294 treatment.

Subsequently, a qPCR experiment was performed to validate the differential expression patterns of the 10 miRNAs. At the time of the experiment, the Taqman miRNA assay for one of the miRNAs (hsa-miR-1229-5p) was not available; therefore, it was excluded from the analysis. In addition, hsa-miR-3613-3p was found to be undetectable in the sample groups in qPCR analysis. The normalized and averaged expression levels of the remaining eight miRNAs are shown in [Fig. 1](#f1-ol-07-06-1819){ref-type="fig"}. Two of the miRNAs, hsa-miR-106b-3p and hsa-miR-151a-3p, exhibited a significant reduction (40 and 33%, respectively) in expression level that is consistent with the result that was obtained from the microarray analysis.

Certain target genes of hsa-miR-151a-3p are associated with cancerous diseases
------------------------------------------------------------------------------

A search was conducted for the genes whose expression may be regulated by these two miRNAs. A total of 14 and 182 genes were predicted to be the targets of hsa-miR-106b-3p and hsa-miR-151a-3p, respectively ([Table II](#tII-ol-07-06-1819){ref-type="table"}). The small number of genes identified for hsa-miR-106b-3p precluded the performance of a robust prediction of the associated biological functions or disorders. A gene ontology analysis of the 182 genes that were potentially regulated by hsa-miR-151a-3p revealed that the most significantly associated biological process was the negative regulation of branching that is involved in ureteric bud morphogenesis. To examine if there is an association of human diseases with the predicted target genes, an enrichment analysis for disease-associated genes was performed. A total of 10 classes of disease (neoplasm metastasis, neoplastic processes, syndrome, adhesion, carcinoma, fasciculation, eye abnormalities, brain injuries, schizophrenia, optic nerve diseases) were found to be associated with the 182 genes. Among these diseases neoplasm metastasis, neoplastic processes, adhesion and carcinoma are relevant to cancer development and propagation. The genes associated with these four diseases are listed in [Table III](#tIII-ol-07-06-1819){ref-type="table"}.

Discussion
==========

The involvement in cell growth and susceptibility to epigenetic dysregulation highlights the role of miRNAs in cancer development. For this reason, these small RNA species may serve as potential therapeutic targets against cancer. The role of H3K9 methylation in the regulation of miRNA expression in human lung cancer cells has not been established. In the present study, it was found that the blockade of G9a activity, and thus histone H3K9 methylation, modulated the expression of miRNAs in the invasive H1299 lung cancer cell line. By interrogating the change in miRNA expression pattern with microarray analysis, it was found that only a particularly small portion of the human miRNA collection (51 out of 2,019; 2.5%) exhibited differential expression following BIX01294 treatment. This observation indicates that the regulatory activity of G9a may be specific towards a subset of miRNAs in these cells. Coupled with qPCR analysis, the two miRNAs that were identified, hsa-miR-106b-3p and hsa-miR-151a-3p, were downregulated in H1299 cells following BIX01294 treatment.

The biological function of hsa-miR-106b-3p and hsa-miR-151a-3p in lung cancer development has not been characterized. Based on their genomic location, hsa-miR-106b-3p and hsa-miR-151a-3p are known to reside in chromosome 7q22.1 and 8q24.3, respectively. The two genomic loci are frequently amplified in various cancers and the overexpression of the embedded genes has been shown to promote malignancy ([@b36-ol-07-06-1819]--[@b40-ol-07-06-1819]). Furthermore, the amplified and overexpressed functional non-coding RNA species participate in cancer development ([@b41-ol-07-06-1819]). Therefore, the downregulation of hsa-miR-106b-3p and hsa-miR-151a-3p expression by BIX01294 treatment may exert a tumor suppressive effect, presumably through the derepression of their target gene expression at the post-transcriptional level. The silencing of G9a expression inhibits the migration and invasion potential of lung cancer cells by enhancing the transactivation of expression of the cell adhesion molecule, epithelial cell adhesion molecule ([@b28-ol-07-06-1819]). It is likely that specific target genes of these miRNAs may encode adhesion molecules, which promote cell-cell adhesion and limit cell motility.

The target genes of hsa-miR-106b-3p and hsa-miR-151a-3p were searched for, and their biological activities and associated human diseases were identified. The small number of genes identified for hsa-miR-106b-3p precluded the performance of a robust prediction of their associated biological functions or human diseases. For hsa-miR-151a-3p, it was found that a subset of its target genes is involved in the cell adhesion process. Notably, certain genes (PCDHB7, PTPN12, CHL1, PPF1A1 and THBS1) encode cell adhesion or cell junction molecules that have been demonstrated or indicated to inhibit cell invasion ([@b42-ol-07-06-1819]--[@b45-ol-07-06-1819]). In addition, the genes exhibiting a similar function (TFAP2C, PCDHB13 and MNT) ([@b46-ol-07-06-1819],[@b47-ol-07-06-1819]) are also target genes of hsa-miR-106b-3p. As a result, the inhibition of G9a activity by BIX01294 treatment may suppress metastasis by downregulating the expression level of miRNAs that block the translation of genes encoding the cell adhesion molecules. By contrast, another subset of the target genes of hsa-miR-151a-3p were identified, which are involved in neoplasm formation and metastasis; however, their involvement in the action of BIX01294 on H1299 cells remains unclear. The extent of derepression of the individual target genes may determine the overall cellular response to the downregulation of hsa-miR-106b-3p and hsa-miR-151a-3p. Alternatively, the biological effect of BIX01294 on H1299 cells may involve the interplay among these gene products.

The change in expression level of specific miRNAs upon inhibition of G9a activity strongly indicates a role for miRNAs in the mediation of the malignancy-promoting effect of G9a. Since mono- and di-methylation of H3K9 are involved in transcriptional silencing ([@b22-ol-07-06-1819]), a blockade of G9a activity, and thus H3K9me1 and H3K9me2 formation, is expected to reactivate the transcription of genes, including miRNAs. By contrast, the mechanism of downregulation of miRNA expression by G9a suppression remains unclear and requires further investigation.

In conclusion, the findings of the present study indicate that the suppression of G9a activity by BIX01294 treatment modulates the expression of specific miRNAs in H1299 cells. Further studies are required to establish the functional role, and prognostic and diagnostic potential of hsa-miR-106b-3p and hsa-miR-151a-3p in lung cancer development.
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###### 

Human miRNAs that showed a differential expression in H1299 cells following BIX01294 treatment through microarray analysis.

  Reporter term                                                   Mock    Treatment   Fold change (Treatment/Mock)   P-value   miRNA sequence (5′ to 3′)                 
  --------------------------------------------------------------- ------- ----------- ------------------------------ --------- --------------------------- ------------- --------------------------
  Transcripts with high microarray signal levels (signal \>500)                                                                                                          
   hsa-miR-15b-3p                                                 604     24          336                            20        0.56                        1.72×10^−5^   CGAAUCAUUAUUUGCUGCUCUA
   hsa-miR-5096                                                   3,782   492         1,289                          318       0.34                        1.40×10^−3^   GUUUCACCAUGUUGGUCAGGC
   hsa-miR-106b-3p                                                545     19          311                            33        0.57                        2.39×10^−3^   CCGCACUGUGGGUACUUGCUGC
   hsa-miR-1229-5p                                                260     29          576                            137       2.22                        4.12×10^−3^   GUGGGUAGGGUUUGGGGGAGAGCG
   hsa-miR-301b                                                   982     50          433                            94        0.44                        5.11×10^−3^   CAGUGCAAUGAUAUUGUCAAAGC
   hsa-miR-188-5p                                                 675     93          1,128                          192       1.67                        5.33×10^−3^   CAUCCCUUGCAUGGUGGAGGG
   hsa-miR-151a-3p                                                665     61          364                            73        0.55                        5.96×10^−3^   CUAGACUGAAGCUCCUUGAGG
   hsa-miR-374c-5p                                                1,257   48          747                            112       0.59                        7.68×10^−3^   AUAAUACAACCUGCUAAGUGCU
   hsa-miR-3613-3p                                                2,960   195         9,363                          3,142     3.16                        8.55×10^−3^   ACAAAAAAAAAAGCCCAACCCUUC
   hsa-miR-1290                                                   1,205   73          2,211                          390       1.83                        9.56×10^−3^   UGGAUUUUUGGAUCAGGGA
  Transcripts with low microarray signal levels (signal \<500)                                                                                                           
   hsa-miR-335-5p                                                 49      13          0                              0         0.00                        1.08×10^−5^   UCAAGAGCAAUAACGAAAAAUGU
   hsa-miR-1207-5p                                                231     12          343                            24        1.49                        2.86×10^−4^   UGGCAGGGAGGCUGGGAGGGG
   hsa-miR-550a-3-5p                                              100     6           157                            13        1.57                        3.07×10^−4^   AGUGCCUGAGGGAGUAAGAG
   hsa-miR-577                                                    44      27          0                              0         0.00                        5.14×10^−4^   UAGAUAAAAUAUUGGUACCUG
   hsa-miR-4440                                                   200     13          147                            9         0.74                        8.02×10^−4^   UGUCGUGGGGCUUGCUGGCUUG
   hsa-miR-1303                                                   108     19          50                             7         0.46                        1.16×10^−3^   UUUAGAGACGGGGUCUUGCUCU
   hsa-miR-5707                                                   253     36          447                            43        1.76                        1.16×10^−3^   ACGUUUGAAUGCUGUACAAGGC
   hsa-miR-501-5p                                                 157     21          89                             12        0.57                        1.48×10^−3^   AAUCCUUUGUCCCUGGGUGAGA
   hsa-miR-16-2-3p                                                393     23          239                            28        0.61                        1.69×10^−3^   CCAAUAUUACUGUGCUGCUUUA
   hsa-miR-657                                                    64      9           34                             5         0.53                        1.71×10^−3^   GGCAGGUUCUCACCCUCUCUAGG
   hsa-miR-4669                                                   254     25          394                            42        1.55                        1.90×10^−3^   UGUGUCCGGGAAGUGGAGGAGG
   hsa-miR-224-5p                                                 368     28          203                            33        0.55                        2.14×10^−3^   CAAGUCACUAGUGGUUCCGUU
   hsa-miR-548au-5p                                               25      19          0                              0         0.00                        2.15×10^−3^   AAAAGUAAUUGCGGUUUUUGC
   hsa-let-7a-3p                                                  120     27          51                             11        0.43                        2.22×10^−3^   CUAUACAAUCUACUGUCUUUC
   hsa-miR-4749-3p                                                166     12          113                            13        0.68                        2.34×10^−3^   CGCCCCUCCUGCCCCCACAG
   hsa-miR-6511b-3p                                               241     48          117                            9         0.49                        2.45×10^−3^   CCUCACCACCCCUUCUGCCUGCA
   hsa-miR-339-5p                                                 233     25          154                            7         0.66                        2.46×10^−3^   UCCCUGUCCUCCAGGAGCUCACG
   hsa-miR-596                                                    154     10          112                            11        0.73                        2.56×10^−3^   AAGCCUGCCCGGCUCCUCGGG
   hsa-miR-101-3p                                                 339     13          185                            23        0.55                        2.76×10^−3^   UACAGUACUGUGAUAACUGAA
   hsa-miR-4258                                                   201     17          134                            16        0.67                        2.99×10^−3^   CCCCGCCACCGCCUUGG
   hsa-miR-339-3p                                                 115     15          71                             10        0.61                        3.48×10^−3^   UGAGCGCCUCGACGACAGAGCCG
   hsa-miR-3156-5p                                                168     12          273                            41        1.62                        3.80×10^−3^   AAAGAUCUGGAAGUGGGAGACA
   hsa-miR-130b-5p                                                228     11          137                            16        0.60                        3.83×10^−3^   ACUCUUUCCCUGUUGCACUAC
   hsa-miR-4417                                                   98      9           132                            10        1.36                        4.41×10^−3^   GGUGGGCUUCCCGGAGGG
   hsa-miR-6073                                                   112     30          318                            94        2.84                        4.64×10^−3^   GGUAGUGAGUUAUCAGCUAC
   hsa-miR-3943                                                   94      10          33                             9         0.35                        4.78×10^−3^   UAGCCCCCAGGCUUCACUUGGCG
   hsa-miR-371a-5p                                                98      9           143                            18        1.45                        5.20×10^−3^   ACUCAAACUGUGGGGGCACU
   hsa-miR-30d-3p                                                 177     12          70                             18        0.40                        5.32×10^−3^   CUUUCAGUCAGAUGUUUGCUGC
   hsa-miR-493-3p                                                 71      13          116                            14        1.63                        5.85×10^−3^   UGAAGGUCUACUGUGUGCCAGG
   hsa-miR-140-3p                                                 283     9           200                            19        0.71                        5.96×10^−3^   UACCACAGGGUAGAACCACGG
   hsa-miR-4278                                                   124     30          307                            88        2.47                        6.25×10^−3^   CUAGGGGGUUUGCCCUUG
   hsa-miR-539-3p                                                 60      23          171                            45        2.86                        6.39×10^−3^   AUCAUACAAGGACAAUUUCUUU
   hsa-miR-654-5p                                                 57      20          19                             7         0.34                        7.03×10^−3^   UGGUGGGCCGCAGAACAUGUGC
   hsa-miR-24-2-5p                                                291     24          192                            28        0.66                        7.33×10^−3^   UGCCUACUGAGCUGAAACACAG
   hsa-miR-140-5p                                                 86      31          27                             8         0.32                        7.62×10^−3^   CAGUGGUUUUACCCUAUGGUAG
   hsa-miR-3162-3p                                                127     6           108                            6         0.85                        7.76×10^−3^   UCCCUACCCCUCCACUCCCCA
   hsa-miR-296-5p                                                 222     28          159                            13        0.72                        8.19×10^−3^   AGGGCCCCCCCUCAAUCCUGU
   hsa-miR-222-5p                                                 237     29          91                             27        0.38                        8.24×10^−3^   CUCAGUAGCCAGUGUAGAUCCU
   hsa-miR-564                                                    285     19          193                            30        0.68                        8.65×10^−3^   AGGCACGGUGUCAGCAGGC
   hsa-miR-642b-3p                                                241     24          333                            40        1.38                        8.93×10^−3^   AGACACAUUUGGAGAGGGACCC
   hsa-miR-576-5p                                                 86      29          25                             13        0.29                        8.96×10^−3^   AUUCUAAUUUCUCCACGUCUUU

SD, standard deviation.

###### 

Putative target genes of hsa-miR-106b-3p and hsa-miR-151a-3p.

  miRNA             Putative target gene
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa-miR-106b-3p   LOC347411, SOCS7, TFAP2C, C15orf26, PCDHB13, C4orf39, RNGTT, ARHGAP17, IRAK2, TNRC6A, BICD2, KCTD2, SLC35A1, MNT
  hsa-miR-151a-3p   UPP2, FXR1, PKN2, ZFAND5, GABRA6, ZMAT1, KCNH8, ME1, CLASP2, ZNF326, PGM3, RPS6KA5, EIF2C2, ATP2A2, CLK1, PITPNA, CHL1, GFM2, DCTN4, ITK, HIF1A, CASD1, FAM104A, LIG4, SIX1, FAM76B, ADAM7, PURB, RGS6, CRK, KLHL4, AQP4, SLC8A1, ANKRD44, PTGER3, HMGN2, OXR1, TRA2B, API5, FAM5C, STXBP4, ZFPM2, RYBP, YSK4, ZNF24, ACTR2, PTPRZ1, ARMC8, NEURL1B, PANK2, PANX3, CAPZA2, ARHGAP23, ZEB1, DISC1, SNX18, MFAP5, FAM59A, TRDN, RERG, FBXL3, QKI, GHR, CCNDBP1, ZNF415, C5orf28, DBT, TSC1, CREBZF, ZNF254, IL26, SPIRE2, PFN2, RBM27, CEP95, RNF20, SOS1, RBM5, DSCC1, CAB39, NKAIN3, PCBP2, CYTIP, LPIN2, C1orf9, PTPN12, MANEA, SOCS5, DTX3L, YTHDF3, SLCO3A1, TWIST1, PRKACB, CUX1, MRPS25, PYROXD1, IKZF3, HSDL1, BTLA, PLEKHF2, CAST, YIPF6, SETD6, C9orf117, GPD2, C3orf43, CGA, CASC4, HMGA2, SPIRE1, DTHD1, OSBPL3, ACAP2, GLS, LOC100506156, SERPINA1, PHC1, FAM199X, SUSD5, RAB3GAP1, KIAA1217, PCDHB7, C15orf41, ECT2L, SIAH3, OPA3, STMN2, FAM211A, LGSN, SLA, NIPBL, SEC22C, BMPR1B, HCCS, ZSCAN29, TAF5L, LOC100653121, PPFIA1, DUSP19, HPDL, UCHL1, HTR1F, SLC35E2B, ZNF345, GREM1, TET2, NIPAL2, LOC100652774, C3orf17, FAM170A, MYLK4, CEACAM5, ARL1, NETO2, SLC35E2, THBS1, C8orf84, SMARCAD1, PGR, TMEM99, KBTBD2, CALD1, DSG3, GRM3, PGM2L1, LAPTM5, UHMK1, TACSTD2, MAGEA2B, FAM120AOS, PAPOLG, C10orf10, ZNF264, MAGEA2, PRR23C, CALCR, PTPRS, RPRD2, TIAM1, NAMPT, MCTP2, RPL27A

###### 

Putative target genes of hsa-miR-151a-3p that are associated with diseases relevant to cancer.

  Human disease          Putative target gene
  ---------------------- --------------------------------------------------------------------------------
  Neoplasm metastasis    SIX1, HIF1A, ZEB1, TACSTD2, TWIST1, CEACAM5, TIAM1, PGR, THBS1
  Neoplastic processes   HMGA2, SIX1, CRK, HIF1A, ZEB1, TWIST1, CEACAM5, TIAM1, PGR, THBS1
  Adhesion               CYTIP, PCDHB7, CRK, PTPN12, TACSTD2, CEACAM5, CHL1, PPFIA1, TIAM1, DSG3, THBS1
  Carcinoma              RBM5, HMGA2, SIX1, HIF1A, ZEB1, TWIST1, CEACAM5, TIAM1, PGR, THBS1
